Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers
Tolba, Mai; Elghazaly, H; Bousoik, E; Elmazar, M M A; Tolaney, S M;
Abstract
The year 2019 witnessed the first approval of an immune checkpoint inhibitor (ICI) for the management of triple negative breast cancers (TNBC) that are metastatic and programmed death ligand (PD)-L1 positive. Extensive research has focused on testing ICI-based combinatorial strategies, with the ultimate goal of enhancing the response of breast tumors to immunotherapy to increase the number of breast cancer patients benefiting from this transformative treatment. The promising investigational strategies included immunotherapy combinations with monoclonal antibodies (mAbs) against human epidermal growth factor receptor (HER)-2 for the HER2 + tumors versus cyclin-dependent kinase (CDK)4/6 inhibitors in the estrogen receptor (ER) + disease. Multiple approaches are showing signals of success in advanced TNBC include employing Poly (ADP-ribose) polymerase (PARP) inhibitors, tyrosine kinase inhibitors, MEK inhibitors, phosphatidylinositol 3‑kinase (PI3K)/protein kinase B (AKT) signaling inhibitors or inhibitors of adenosine receptor, in combination with the classical PD-1/PD-L1 immune checkpoint inhibitors. Co-treatment with chemotherapy, high intensity focused ultrasound (HIFU) or interleukin-2-βɣ agonist have also produced promising outcomes. This review highlights the latest combinatorial strategies under development for overcoming cancer immune evasion and enhancing the percentage of immunotherapy responders in the different subsets of advanced breast cancers.
Other data
Title | Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers | Authors | Tolba, Mai ; Elghazaly, H; Bousoik, E; Elmazar, M M A; Tolaney, S M | Keywords | Breast cancer;Immunotherapy;Trastuzumab;PARP inhibitors;Immune checkpoint inhibitors;Cabozantinib | Issue Date | Oct-2021 | Journal | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | ISSN | 1699-048X 1699-3055 |
DOI | 10.1007/s12094-021-02613-w | PubMed ID | 33871826 | Scopus ID | 2-s2.0-85111746439 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.